Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | VSIR | Q9H7M9 | 10/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664072 | 0.92 | SCN8A (0.46) | PRMT6EPHX2VSIRSCN8ACD274 | |
| SCHEMBL3663779 | 0.85 | FFAR1 (0.42) | PRMT6EPHX2VSIRSCN8ACD274 | |
| SCHEMBL3666063 | 0.83 | SMN1; SMN2 (0.51) | VSIRCD274PDCD1SMN1; SMN2 | |
| SCHEMBL3666969 | 0.82 | VSIR (0.43) | PRMT6EPHX2VSIRSCN8ACD274 | |
| SCHEMBL3724194 | 0.82 | PRMT6 (0.66) | PRMT6EPHX2SCN8ABACE1 | |
| SCHEMBL3666218 | 0.82 | PRKCI (0.56) | PRMT6EPHX2 | |
| SCHEMBL4152914 | 0.79 | PRMT6 (0.43) | PRMT6EPHX2VSIRSCN8ACD274 | |
| SCHEMBL13778409 | 0.77 | SCN8A (0.49) | PRMT6EPHX2VSIRSCN8ACD274 | |
| SCHEMBL29142174 | 0.77 | CHRM2 (0.38) | SCN8ACD274PDCD1SMN1; SMN2 | |
| SCHEMBL3667002 | 0.76 | CYP2A6 (0.44) | PRMT6EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101970435-B | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2014-07-02 | — | — | CN | claimed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | claimed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | claimed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | claimed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | PRMT6 1956/4885EPHX2 3222/4885VSIR 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.